Blue Matter Consulting is a management consulting firm dedicated to the life sciences industry, particularly in pharmaceuticals and biotechnology. Founded in 2012, the company has grown from a single office to a global presence with locations in the United States, Europe, and India. The leadership team, including managing partners Ashwin Dandekar, Emily Hua, and George Schmidt, guides the firms strategic growth. The firm offers a wide range of services to help life sciences companies maximize value. These services include new product planning, launch strategy and management, commercial strategy for existing products, market access strategy, corporate strategy, transaction support, and organizational design. Blue Matter also focuses on specific therapeutic areas such as oncology and rare diseases, providing tailored strategies and solutions. With a diverse client base of over 250 companies, including many top global biopharmaceutical firms, Blue Matter Consulting is recognized for its strategic expertise and personalized service in the life sciences sector.
Oden Machinery, Inc. provides customers worldwide with liquid filling and processing machinery backed by over three decades of industry-leading innovation in design and engineering solutions. Oden is a leading U.S. manufacturer of filling and processing machinery for the liquid products markets and provides complete turnkey liquid packaging lines. Custom designed systems for form/fill/seal, bag-in-box, retort, explosion proof, and other specialized liquid packaging applications are also available. In August 2010, Oden partnered with Green Frontier LLC to help companies optimize their liquid processing operations and reduce their impact on the environment. The Oden Process Equipment Group offers continuous stream digital blending systems, automated batch addition systems, and liquid product transfer systems, all designed to reduce labor costs, enhance product quality, increase production capacity, and decrease generation of waste and scrap. Our customers businesses span a broad range of industries, including pharmaceutical, personal care products, food processing, household products, general industrial, automotive products, petroleum products, and the chemical processing industries. If your packaging/processing operations include filling or processing liquid products, we encourage you to visit www.odencorp.com. If you need an off the shelf" machine or require highly specialized machinery give us a call, 800-658-3622.
VFO LLC provides accounting and finance services to early stage start-up companies in any industry. From day-to-day bookkeeping activity to financial forecasts.
Crossroads Automotive Group Inc. is a privately-held automotive dealership group based in Sanford, North Carolina, founded in 1996. The company specializes in new and used vehicle sales, service, and collision repair, operating multiple locations across North Carolina and Virginia. With a workforce of approximately 1,345 employees, Crossroads Automotive Group generates annual revenue of about $232 million. The company is committed to a customer-centric vehicle buying experience, guided by Christian principles. It emphasizes hiring skilled staff, maintaining large inventories, and providing compassionate service. Crossroads Automotive Group has expanded through acquisitions, including brands like Ford, Lincoln, INFINITI, Chrysler, Dodge, Jeep, and Ram. In addition to vehicle sales, the company offers automotive service, collision repair, maintenance, and financing options. It operates under various names, including Crossroads Ford and Crossroads Auto Group, and has established a strong presence in the automotive market.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.